AU2010202277B2 — Chemically modified small molecules
Assigned to Nektar Therapeutics · Expires 2013-03-21 · 13y expired
What this patent protects
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administra…
USPTO Abstract
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer. 22427731 (GHMatters) 1106/10 Relative oral bioavailability of 13-cis-RA and PEGn-13-cis-RA in rats, (±SEM bars, Dose=6mg/Kq) 0) Tie hr FI-
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.